Mutations in the p53 Gene in Skin Cancers from Arsenic Exposure
Author Information
Author(s): Hsu C-H, Yang S-A, Wang J-Y, Yu H-S, Lin S-R
Primary Institution: Kaohsiung Medical College
Hypothesis
To understand the role of the p53 tumour suppressor gene in the carcinogenesis of arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Conclusion
The study found a high rate of p53 gene mutations in arsenic-related skin cancers, differing from those in UV-induced skin cancers.
Supporting Evidence
- p53 gene mutations were found in 39% of cases with Bowen's disease.
- 28.6% of cases with basal cell carcinomas had p53 mutations.
- 55.6% of cases with squamous cell carcinomas showed p53 mutations.
- Most mutations were located on exon 5 and exon 8.
- Missense mutations were identified at several codons including 149, 175, 273, 292, 283, 172, and 284.
- Silent mutations were found in four cases at codons 174, 253, 289, and 298.
- p53 overexpression was found in 43.5% of Bowen's disease cases.
- The mutation types in arsenic-related skin cancers differ from those in UV-induced skin cancers.
Takeaway
Scientists looked at skin cancer samples from people exposed to arsenic and found many had changes in a gene that helps prevent cancer.
Methodology
Tumour samples were collected from patients with Bowen's disease, basal cell carcinomas, and squamous cell carcinomas, followed by sequencing and immunohistochemistry analysis.
Participant Demographics
Patients included 23 with Bowen's disease, 7 with basal cell carcinomas, and 9 with squamous cell carcinomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website